AAS
OVID icon

Avantax Advisory Services’s Ovid Therapeutics OVID Stock Holding History

Avantax Advisory Services’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$5.61K Buy
+17,000
New +$5.12K ﹤0.01% 2357

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Avantax Advisory Services's OVID Position: Q2 2025 in Review

Avantax Advisory Services opened a new position in Ovid Therapeutics (OVID) in Q2 2025: 17,000 shares worth $5.61K. The stake represents ﹤0.01% of the portfolio and ranks #2357 among its holdings.

71 funds tracked by Wall St. Rank hold OVID as of Q2 2025.

  • Avantax Advisory Services held 17,000 shares of Ovid Therapeutics worth $5.61K as of Q2 2025.
  • Ovid Therapeutics was a new Avantax Advisory Services position in Q2 2025.
  • Ovid Therapeutics made up ﹤0.01% of Avantax Advisory Services's portfolio in Q2 2025, its #2357 holding.
  • 71 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2025.

Based on Avantax Advisory Services's 13F filing for Q2 2025, filed 8 Aug 2025.